Stay informed, stay ahead.
Merck and Eisai have stopped a major late-stage trial for their liver cancer treatment after early results showed the drug combination was unlikely to improve patient survival. The two companies were testing Keytruda, Merck’s top immunotherapy drug, with Eisai’s cancer medicine Lenvima. The goal was to see whether the combination could help patients with hepatocellular…
Merck has begun work on a $3 billion manufacturing facility in Elkton, Virginia, as part of its plan to ramp up U.S. production. The new plant will span about 400,000 square feet and focus on small-molecule drug manufacturing and testing. Merck said the investment will create over 500 full-time jobs and roughly 8,000 construction roles…
The U.S. Food and Drug Administration (FDA) has selected nine drugs for expedited review under its new National Priority Voucher pilot program, designed to fast-track treatments that address major health needs. Instead of the typical 10–12 month review, these drugs could be approved in one to two months. The FDA says the program will use…
The White House and Merck KGaA announced an agreement Thursday aimed at dramatically reducing prices for in vitro fertilization (IVF) medications in the U.S. The effort is part of a broader push to make fertility treatment more affordable and accessible. Under the deal, Merck — via its U.S. arm EMD Serono — will offer key…
